BridgeBio Pharma Inc
NASDAQ:BBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
US |
|
A
|
Ansell Ltd
OTC:ANSLY
|
AU |
|
L
|
Lennar Corp
BMV:LEN
|
US |
|
Extendicare Inc
TSX:EXE
|
CA |
Intrinsic Value
Is BBIO undervalued or overvalued?
See the intrinsic value estimate for BridgeBio Pharma Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
BBIO looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with BBIO’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What BridgeBio Pharma Does
BridgeBio Pharma is a biotechnology company that focuses on genetic diseases, especially conditions caused by a single faulty gene. It discovers and develops medicines for rare and serious disorders, then seeks approval and commercial launches for the programs that work. Its work covers both early research and later-stage drug development, with a strong focus on diseases where the biology is clear and the patient groups are small.
- Headquarters
- United States of America US
- Employees
- 834
- IPO date
- Jun 27, 2019
BridgeBio Pharma has no economic moat
BridgeBio’s medicines compete on their individual clinical merits, but more patients using one product does not make it more valuable to others, and rival treatments can still pursue the same patients. The markets it serves can support competing drug makers, so its size alone does not keep newcomers out.
Read the full moat analysis
Revenue & Expenses Breakdown
BridgeBio Pharma Inc
Earnings Waterfall
BridgeBio Pharma Inc
The intrinsic value for BridgeBio Pharma Inc (BBIO) under the Base Case is hidden USD.
Compared with the current market price of 68.165 USD, the stock appears hidden.